Buch P, Holm P, Thomassen J Q, Scherer D, Kataoka M, Yamashita S, Langguth P
Department of Pharmaceutical Technology and Biopharmaceutics', Johannes Gutenberg-University, Mainz, Germany.
Pharmazie. 2010 Oct;65(10):723-8.
In a previous study it has been demonstrated that a dissolution/permeation (D/P) system can discriminate between different immediate release fenofibrate formulations. The fractions permeated were correlated with fenofibrate's in vivo exposure in rats following p.o. administration. In the present study more detailed investigations are presented using data from six fenofibrate tablets tested in vivo in humans. In these pharmacokinetic studies no significant differences between formulations in AUC but in Cmax were found. Differences between the Cmax values were not explained by the dissolution characteristics of the tablets but were rationalized on the basis of micellar entrapment and diminished mobility of the active ingredient by surfactants in the formulations. This was demonstrated by a permeation system using dialysis membranes. Thus a permeation step in addition to dissolution measurement may significantly improve the establishment of an IVIV relationship.
在先前的一项研究中已证明,溶出/渗透(D/P)系统能够区分不同的非诺贝特速释制剂。渗透分数与大鼠口服给药后非诺贝特的体内暴露量相关。在本研究中,使用在人体中进行体内测试的六种非诺贝特片剂的数据进行了更详细的研究。在这些药代动力学研究中,各制剂之间在AUC方面未发现显著差异,但在Cmax方面存在差异。Cmax值之间的差异并非由片剂的溶出特性所解释,而是基于胶束包封以及制剂中表面活性剂使活性成分的迁移性降低而得到合理说明。这通过使用透析膜的渗透系统得到了证明。因此,除溶出度测量外增加一个渗透步骤可能会显著改善体内体外相关性的建立。